M
Maureen E. Trudeau
Researcher at Sunnybrook Health Sciences Centre
Publications - 259
Citations - 14303
Maureen E. Trudeau is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 51, co-authored 235 publications receiving 12424 citations. Previous affiliations of Maureen E. Trudeau include York University & Women's College Hospital.
Papers
More filters
Journal ArticleDOI
RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy
Kenneth P.H. Pritzker,Laura B Pritzker,Daniele Generali,Alberto Bottini,Maria Rosa Cappelletti,Baoqing Guo,Amadeo M. Parissenti,Maureen E. Trudeau +7 more
TL;DR: RDA is a novel intermediate endpoint that has promise for clinical utility for breast cancers early in response-guided primary systemic therapy and can stratify at midtherapy, pCR responders from non-pCR responders irrespective of clinical response.
Journal ArticleDOI
The impact of cancer drug wastage on economic evaluations.
Judy Truong,Judy Truong,Matthew C. Cheung,Matthew C. Cheung,Matthew C. Cheung,Helen Mai,Jessa Letargo,Alexandra Chambers,Mona Sabharwal,Maureen E. Trudeau,Maureen E. Trudeau,Kelvin K. W. Chan +11 more
TL;DR: The objective of this study was to determine the impact of modeling cancer drug wastage in economic evaluations because wastage can result from single‐dose vials on account of body surface area– or weight‐based dosing.
Journal ArticleDOI
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
Wei Fang Dai,Jaclyn Beca,Chenthila Nagamuthu,Ning Li,Claire de Oliveira,Craig C. Earle,Maureen E. Trudeau,Kelvin K. W. Chan +7 more
TL;DR: It is suggested that pertuzumab may increase survival for patients with metastatic breast cancer but would not be considered cost-effective, even after 100% price reduction, under conventional thresholds.
Journal ArticleDOI
Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D
TL;DR: FEC-D with PP starting with the first cycle of D is most likely to be cost-effective, especially with increased risk of FN and mortality from FN, but is robust to uncertainty in parameters related to breast cancer, such as the utilities and hazard of relapse.
Journal ArticleDOI
End-of-life home care utilization and costs in patients with advanced colorectal cancer.
Nicole Mittmann,Ning Liu,Joan Porter,Pierre K. Isogai,Refik Saskin,Matthew C. Cheung,Natasha B. Leighl,Jeffrey S Hoch,Jeffrey S Hoch,Maureen E. Trudeau,William K. Evans,Katie N. Dainty,Craig C. Earle +12 more
TL;DR: Overall utilization and costs associated with home care services in Ontario, Canada by linking a home care database to a stage IV colorectal cancer cohort showed male sex, a history of moderate or high utilization of health care services, and hospitalization were associated with lower home care costs.